Bromhexine 8mg tablets
Prescription only
Requires a prescription from a doctor or prescriber
Tablet
8mg
Oral
Bromhexine is mucolytic agent used for a variety of respiratory conditions associated with increased mucus secretion.
Active ingredients:
Bromhexine
No active safety alerts
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
MHRA
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Bromhexine
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
EMA
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Bromhexine
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Show details
Therapeutically similar medicines
Show details
Acetylcysteine 200mg oral powder sachets
Powder
200mg
Same therapeutic group
Carbocisteine 750mg capsules
Capsule
750mg
Same therapeutic group
Carbocisteine 250mg/5ml oral solution sugar free
Oral solution
250mg/5ml
Same therapeutic group
Carbocisteine 750mg/5ml oral solution sugar free
Oral solution
750mg/5ml
Same therapeutic group
Acetylcysteine 600mg effervescent tablets sugar free
Tablet
600mg
Same therapeutic group
Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
Clinical guidelines and formulary information
British National Formulary
Bromhexine
BNF
Drug monograph — bnf.nice.org.ukSource: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Show details
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & product information
Official product databases and supply status monitoring
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.
Codes for healthcare professionals and prescribing systems
Show details
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Show details
Searching UK clinical trials...
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
31.4 hours
Mechanism
Inflammation of the airways, increased mucus secretion, and altered mucociliary…
Food interactions
None known
Human targets
2 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
8-32 mg
After oral administration, bromhexine demonstrates linear pharmacokinetics when given in doses of 8-32 mg.…
Half-life
32 mg
Following single oral doses ranging from 8 and 32 mg, the terminal half-life of bromhexine has been measured between 6.6 and 31.4 hours.
[L33060]
[L33060]
Protein binding
95%
Bromhexine is approximately 95% bound to plasma proteins.
[L33060]
[L33060]
Volume of distribution
206 L
After intravenous administration in a pharmacokinetic study, bromhexine was found to be widely distributed.…
Metabolism
Bromhexine is almost completely metabolized to a variety of hydroxylated metabolites in addition to dibromanthranilic acid.…
Elimination
97%
After a dose of bromhexine was administered during a pharmacokinetic study, approximately 97% of the radiolabeled dose was detected in the urine; under 1% was detected as the parent drug.
[L33060]…
[L33060]…
Clearance
843-1073 mL/min
The clearance of bromhexine ranges from 843-1073 mL/min, within the range of the hepatic circulation.
[L33060]
[L33060]
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Status:
Approved
Small molecule
About this compound
Bromhexine is mucolytic agent used for a variety of respiratory conditions associated with increased mucus secretion. It is derived from the Adhatoda vasica plant and aids in the clearance of excess mucus, improving breathing and reducing cough. It was introduced into the market in 1963, and is widely available as an over-the-counter drug in many countries.[A233240] Recently, bromhexine and its metabolite [ambroxol] have garnered interest for the potential prevention and treatment of COVID-19 due to their interactions with cell receptors in the lungs.[A233345][A233370]
Properties:
solid
Avg. mass: 376.13 Da
DrugBank indication
Bromohexine is used alone or with other ingredients such as [diphenhydramine], [dextromethorphan], and [guaifenesin] to reduce mucus viscosity and clear mucus in conditions associated with mucus hypersecretion, including the common cold, influenza, respiratory tract infections, or other conditions.
[L29975][L24819][L33060]
[L29975][L24819][L33060]
Also known as(21)
3,5-dibromo-N(alpha)-cyclohexyl-N(alpha)-methyltoluene-alpha-2-diamine
Bromexina
Bromhexina
Bromhexine
Bromhexinum
N-cyclohexyl-N-methyl-(2-amino-3,5-dibrombenzyl)amine
3.4.21.122
PRSS10
Dosage forms(89)
Suspension (Oral) — 3.000 g
Syrup (Oral) — 4 mg/5mL
Suspension (Oral) — 5.0000 g
Granule — 8 MG
Injection (Intramuscular; Intravenous) — 2 MG/ML
Injection, solution (Parenteral) — 4 MG/2ML
Solution (Respiratory (inhalation)) — 0.200 g
Suppository (Rectal) — 16 mg
Molecular properties(19)
Drug interactions(328)
Known interactions with other medications. Always consult a healthcare professional.
Gramicidin D
Moderate
Bromhexine may increase the excretion rate of Gramicidin D which could result in a lower serum level and potentially a reduction in efficacy.
Daptomycin
Moderate
Bromhexine may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.
Azithromycin
Moderate
Bromhexine may increase the excretion rate of Azithromycin which could result in a lower serum level and potentially a reduction in efficacy.
Moxifloxacin
Moderate
Bromhexine may increase the excretion rate of Moxifloxacin which could result in a lower serum level and potentially a reduction in efficacy.
Bromhexine may increase the excretion rate of Cefotiam which could result in a lower serum level and potentially a reduction in efficacy.
Aminosalicylic acid
Moderate
Bromhexine may increase the excretion rate of Aminosalicylic acid which could result in a lower serum level and potentially a reduction in efficacy.
Bromhexine may increase the excretion rate of Dapsone which could result in a lower serum level and potentially a reduction in efficacy.
Doxycycline
Moderate
Bromhexine may increase the excretion rate of Doxycycline which could result in a lower serum level and potentially a reduction in efficacy.
Lymecycline
Moderate
Bromhexine may increase the excretion rate of Lymecycline which could result in a lower serum level and potentially a reduction in efficacy.
Sulfanilamide
Moderate
Bromhexine may increase the excretion rate of Sulfanilamide which could result in a lower serum level and potentially a reduction in efficacy.
Cycloserine
Moderate
Bromhexine may increase the excretion rate of Cycloserine which could result in a lower serum level and potentially a reduction in efficacy.
Sulfisoxazole
Moderate
Bromhexine may increase the excretion rate of Sulfisoxazole which could result in a lower serum level and potentially a reduction in efficacy.
Cefmenoxime
Moderate
Bromhexine may increase the excretion rate of Cefmenoxime which could result in a lower serum level and potentially a reduction in efficacy.
Cefmetazole
Moderate
Bromhexine may increase the excretion rate of Cefmetazole which could result in a lower serum level and potentially a reduction in efficacy.
Flucloxacillin
Moderate
Bromhexine may increase the excretion rate of Flucloxacillin which could result in a lower serum level and potentially a reduction in efficacy.
Bromhexine may increase the excretion rate of Ertapenem which could result in a lower serum level and potentially a reduction in efficacy.
Capreomycin
Moderate
Bromhexine may increase the excretion rate of Capreomycin which could result in a lower serum level and potentially a reduction in efficacy.
Piperacillin
Moderate
Bromhexine may increase the excretion rate of Piperacillin which could result in a lower serum level and potentially a reduction in efficacy.
Ethambutol
Moderate
Bromhexine may increase the excretion rate of Ethambutol which could result in a lower serum level and potentially a reduction in efficacy.
Pyrazinamide
Moderate
Bromhexine may increase the excretion rate of Pyrazinamide which could result in a lower serum level and potentially a reduction in efficacy.
Bromhexine may increase the excretion rate of Aztreonam which could result in a lower serum level and potentially a reduction in efficacy.
Sulfadiazine
Moderate
Bromhexine may increase the excretion rate of Sulfadiazine which could result in a lower serum level and potentially a reduction in efficacy.
Grepafloxacin
Moderate
Bromhexine may increase the excretion rate of Grepafloxacin which could result in a lower serum level and potentially a reduction in efficacy.
Bromhexine may increase the excretion rate of Mupirocin which could result in a lower serum level and potentially a reduction in efficacy.
Phenoxymethylpenicillin
Moderate
Bromhexine may increase the excretion rate of Phenoxymethylpenicillin which could result in a lower serum level and potentially a reduction in efficacy.
Cefpiramide
Moderate
Bromhexine may increase the excretion rate of Cefpiramide which could result in a lower serum level and potentially a reduction in efficacy.
Ceftazidime
Moderate
Bromhexine may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.
Chloramphenicol
Moderate
Bromhexine may increase the excretion rate of Chloramphenicol which could result in a lower serum level and potentially a reduction in efficacy.
Loracarbef
Moderate
Bromhexine may increase the excretion rate of Loracarbef which could result in a lower serum level and potentially a reduction in efficacy.
Framycetin
Moderate
Bromhexine may increase the excretion rate of Framycetin which could result in a lower serum level and potentially a reduction in efficacy.
Clomocycline
Moderate
Bromhexine may increase the excretion rate of Clomocycline which could result in a lower serum level and potentially a reduction in efficacy.
Bromhexine may increase the excretion rate of Cefalotin which could result in a lower serum level and potentially a reduction in efficacy.
Bromhexine may increase the excretion rate of Enoxacin which could result in a lower serum level and potentially a reduction in efficacy.
Bromhexine may increase the excretion rate of Amikacin which could result in a lower serum level and potentially a reduction in efficacy.
Dicloxacillin
Moderate
Bromhexine may increase the excretion rate of Dicloxacillin which could result in a lower serum level and potentially a reduction in efficacy.
Pefloxacin
Moderate
Bromhexine may increase the excretion rate of Pefloxacin which could result in a lower serum level and potentially a reduction in efficacy.
Cefotaxime
Moderate
Bromhexine may increase the excretion rate of Cefotaxime which could result in a lower serum level and potentially a reduction in efficacy.
Vancomycin
Moderate
Bromhexine may increase the excretion rate of Vancomycin which could result in a lower serum level and potentially a reduction in efficacy.
Bromhexine may increase the excretion rate of Cefdinir which could result in a lower serum level and potentially a reduction in efficacy.
Ciprofloxacin
Moderate
Bromhexine may increase the excretion rate of Ciprofloxacin which could result in a lower serum level and potentially a reduction in efficacy.
Tigecycline
Moderate
Bromhexine may increase the excretion rate of Tigecycline which could result in a lower serum level and potentially a reduction in efficacy.
Carbenicillin
Moderate
Bromhexine may increase the excretion rate of Carbenicillin which could result in a lower serum level and potentially a reduction in efficacy.
Oxytetracycline
Moderate
Bromhexine may increase the excretion rate of Oxytetracycline which could result in a lower serum level and potentially a reduction in efficacy.
Bromhexine may increase the excretion rate of Linezolid which could result in a lower serum level and potentially a reduction in efficacy.
Bromhexine may increase the excretion rate of Nafcillin which could result in a lower serum level and potentially a reduction in efficacy.
Ethionamide
Moderate
Bromhexine may increase the excretion rate of Ethionamide which could result in a lower serum level and potentially a reduction in efficacy.
Bromhexine may increase the excretion rate of Rifabutin which could result in a lower serum level and potentially a reduction in efficacy.
Demeclocycline
Moderate
Bromhexine may increase the excretion rate of Demeclocycline which could result in a lower serum level and potentially a reduction in efficacy.
Bacitracin
Moderate
Bromhexine may increase the excretion rate of Bacitracin which could result in a lower serum level and potentially a reduction in efficacy.
Sulfacetamide
Moderate
Bromhexine may increase the excretion rate of Sulfacetamide which could result in a lower serum level and potentially a reduction in efficacy.
Showing 50 of 328 interactions
Toxicity & overdose
The oral LD50 of bromhexine in rats is 6 g/kg.
[L33125]
The observed symptoms of accidental overdose with bromhexine are consistent with the
known adverse effects of bromhexine, including headache, nausea, and vomiting, among other symptoms. Provide symptomatic treatment and contact poison control services if an overdose is confirmed or suspected.
[L33060]
[L33125]
The observed symptoms of accidental overdose with bromhexine are consistent with the
known adverse effects of bromhexine, including headache, nausea, and vomiting, among other symptoms. Provide symptomatic treatment and contact poison control services if an overdose is confirmed or suspected.
[L33060]
How it works
Mechanism of action
Inflammation of the airways, increased mucus secretion, and altered mucociliary clearance are the hallmarks of various diseases of the respiratory tract. Mucus clearance is necessary for lung health; bromhexine aids in mucus clearance by reducing the viscosity of mucus and activating the ciliary epithelium[L33060], allowing secretions to be expelled from the respiratory tract.[A233240]
Recent have studies have demonstrated that bromhexine inhibits the transmembrane serine protease 2 receptor (TMPRSS2) in humans. Activation of TMPRSS2 plays an important role in viral respiratory diseases such as influenza A and Middle East Respiratory Syndrome (MERS). Inhibition of receptor activation and viral entry by bromhexine may be effective in preventing or treating various respiratory illnesses, including COVID-19.[A233345][A233350] In vitro studies have suggested the action of ambroxol (a metabolite of bromhexine) on the angiogensin-converting enzyme receptor 2 (ACE2), prevents entry of the viral envelope-anchored spike glycoprotein of SARS-Cov-2 into alveolar cells or increases the secretion of surfactant, preventing viral entry.[A233365 ,A233370]
Recent have studies have demonstrated that bromhexine inhibits the transmembrane serine protease 2 receptor (TMPRSS2) in humans. Activation of TMPRSS2 plays an important role in viral respiratory diseases such as influenza A and Middle East Respiratory Syndrome (MERS). Inhibition of receptor activation and viral entry by bromhexine may be effective in preventing or treating various respiratory illnesses, including COVID-19.[A233345][A233350] In vitro studies have suggested the action of ambroxol (a metabolite of bromhexine) on the angiogensin-converting enzyme receptor 2 (ACE2), prevents entry of the viral envelope-anchored spike glycoprotein of SARS-Cov-2 into alveolar cells or increases the secretion of surfactant, preventing viral entry.[A233365 ,A233370]
Pharmacodynamics
Bromhexine thins airway secretions, improving breathing and discomfort associated with thick mucus in airways associated with a variety of respiratory conditions.[A233240][L26346][L33060]
Pharmacokinetics
How the body processes this drug — absorption, distribution, metabolism, and elimination
Absorption
After oral administration, bromhexine demonstrates linear pharmacokinetics when given in doses of 8-32 mg. Bromhexine is readily absorbed in the gastrointestinal tract at a rapid rate. This drug undergoes extensive first-pass effect in the range of 75-80%.
[A233285][L33060]
The bioavailability is therefore reduced to approximately 22-27%.
[L33060]
[A233285][L33060]
The bioavailability is therefore reduced to approximately 22-27%.
[L33060]
Half-life
Following single oral doses ranging from 8 and 32 mg, the terminal half-life of bromhexine has been measured between 6.6 and 31.4 hours.
[L33060]
[L33060]
Protein binding
Bromhexine is approximately 95% bound to plasma proteins.
[L33060]
[L33060]
Volume of distribution
After intravenous administration in a pharmacokinetic study, bromhexine was found to be widely distributed. Bromhexine is known to cross the blood-brain barrier; small concentrations may cross the placenta. The average volume of distribution of bromhexine was 1209 ± 206 L (19 L/kg).
Lung tissue concentrations of bromhexine two hours after a dose were 1.5 to 3.2 times higher in bronchial tissues than plasma concentrations. Pulmonary parynchema concentrations were 3.4 to 5.9 times higher when compared to plasma concentrations.
[L33060]
Lung tissue concentrations of bromhexine two hours after a dose were 1.5 to 3.2 times higher in bronchial tissues than plasma concentrations. Pulmonary parynchema concentrations were 3.4 to 5.9 times higher when compared to plasma concentrations.
[L33060]
Metabolism
Bromhexine is almost completely metabolized to a variety of hydroxylated metabolites in addition to dibromanthranilic acid. Ambroxol is a known metabolite of bromhexine.
[L33060]
In one study of human plasma, (E)-4-hydroxydemethylbromhexine (E-4-HDMB) and (E)-3-hydroxydemethylbromhexine (E-3-HDMB) were quantified as major metabolites of ambroxol, and (Z)-4-hydroxydemethylbromhexine and (Z)-3-hydroxydemethylbromhexine were quantified as minor metabolites.
[A233340]
[L33060]
In one study of human plasma, (E)-4-hydroxydemethylbromhexine (E-4-HDMB) and (E)-3-hydroxydemethylbromhexine (E-3-HDMB) were quantified as major metabolites of ambroxol, and (Z)-4-hydroxydemethylbromhexine and (Z)-3-hydroxydemethylbromhexine were quantified as minor metabolites.
[A233340]
Route of elimination
After a dose of bromhexine was administered during a pharmacokinetic study, approximately 97% of the radiolabeled dose was detected in the urine; under 1% was detected as the parent drug.
[L33060]
[L33060]
Clearance
The clearance of bromhexine ranges from 843-1073 mL/min, within the range of the hepatic circulation.
[L33060]
[L33060]
Drug targets(2)
Proteins and enzymes this drug interacts with in the body
Transmembrane protease serine 2
TMPRSS2
inhibitor
Specific functionserine-type endopeptidase activity
Cellular location
Cell membrane
General function & pharmacology
Plasma membrane-anchored serine protease that cleaves at arginine residues .
PMID:32703818 PMID:35676539 PMID:37990007 PMID:38964328
Participates in proteolytic cascades of relevance for the normal physiologic function of the prostate .
PMID:25122198
Androgen-induced TMPRSS2 activates several substrates that include pro-hepatocyte growth factor/HGF, the protease activated receptor-2/F2RL1 or matriptase/ST14 leading to extracellular matrix disruption and metastasis of prostate cancer cells .
PMID:15537383 PMID:25122198 PMID:26018085
In addition, activates trigeminal neurons and contribute to both spontaneous pain and mechanical allodynia (By similarity)
PMID:32703818 PMID:35676539 PMID:37990007 PMID:38964328
Participates in proteolytic cascades of relevance for the normal physiologic function of the prostate .
PMID:25122198
Androgen-induced TMPRSS2 activates several substrates that include pro-hepatocyte growth factor/HGF, the protease activated receptor-2/F2RL1 or matriptase/ST14 leading to extracellular matrix disruption and metastasis of prostate cancer cells .
PMID:15537383 PMID:25122198 PMID:26018085
In addition, activates trigeminal neurons and contribute to both spontaneous pain and mechanical allodynia (By similarity)
Angiotensin-converting enzyme 2
ACE2
binder
Specific functioncarboxypeptidase activity
Cellular location
Secreted
General function & pharmacology
Essential counter-regulatory carboxypeptidase of the renin-angiotensin hormone system that is a critical regulator of blood volume, systemic vascular resistance, and thus cardiovascular homeostasis .
PMID:27217402
Converts angiotensin I to angiotensin 1-9, a nine-amino acid peptide with anti-hypertrophic effects in cardiomyocytes, and angiotensin II to angiotensin 1-7, which then acts as a beneficial vasodilator and anti-proliferation agent, counterbalancing the actions of the vasoconstrictor angiotensin II .
PMID:10924499 PMID:10969042 PMID:11815627 PMID:14504186 PMID:19021774
Also removes the C-terminal residue from three other vasoactive peptides, neurotensin, kinetensin, and des-Arg bradykinin, but is not active on bradykinin .
PMID:10969042 PMID:11815627
Also cleaves other biological peptides, such as apelins (apelin-13, [Pyr1]apelin-13, apelin-17, apelin-36), casomorphins (beta-casomorphin-7, neocasomorphin) and dynorphin A with high efficiency .
PMID:11815627 PMID:27217402 PMID:28293165
In addition, ACE2 C-terminus is homologous to collectrin and is responsible for the trafficking of the neutral amino acid transporter SL6A19 to the plasma membrane of gut epithelial cells via direct interaction, regulating its expression on the cell surface and its catalytic activity PMID:18424768 PMID:19185582
PMID:27217402
Converts angiotensin I to angiotensin 1-9, a nine-amino acid peptide with anti-hypertrophic effects in cardiomyocytes, and angiotensin II to angiotensin 1-7, which then acts as a beneficial vasodilator and anti-proliferation agent, counterbalancing the actions of the vasoconstrictor angiotensin II .
PMID:10924499 PMID:10969042 PMID:11815627 PMID:14504186 PMID:19021774
Also removes the C-terminal residue from three other vasoactive peptides, neurotensin, kinetensin, and des-Arg bradykinin, but is not active on bradykinin .
PMID:10969042 PMID:11815627
Also cleaves other biological peptides, such as apelins (apelin-13, [Pyr1]apelin-13, apelin-17, apelin-36), casomorphins (beta-casomorphin-7, neocasomorphin) and dynorphin A with high efficiency .
PMID:11815627 PMID:27217402 PMID:28293165
In addition, ACE2 C-terminus is homologous to collectrin and is responsible for the trafficking of the neutral amino acid transporter SL6A19 to the plasma membrane of gut epithelial cells via direct interaction, regulating its expression on the cell surface and its catalytic activity PMID:18424768 PMID:19185582
Metabolizing enzymes(1)
Enzymes involved in drug metabolism — important for understanding drug interactions
Enzyme activity key
substrate
inhibitor
inducer
ACE2Angiotensin-converting enzyme 2
binder
Scientific references(10)
Zanasi A., Mazzolini M., Kantar A.
A reappraisal of the mucoactive activity and clinical efficacy of bromhexine.
Multidiscip Respir Medicine
2017 Mar 2012:7. doi: 10.1186/s40248-017-0088-1. eCollection 2017
Ansarin K., Tolouian R., Ardalan M., Taghizadieh A., Varshochi M., Teimouri S., Vaezi T., Valizadeh H., Saleh P., Safiri S., Chapman K.R.
Effect of bromhexine on clinical outcomes and mortality in COVID-19 patients: A randomized clinical trial.
Bioimpacts
202010(4):209-215. doi: 10.34172/bi.2020.27. Epub 2020 Jul 19
Bechgaard E., Nielsen A.
Bioavailability of bromhexine tablets and preliminary pharmacokinetics in humans.
Biopharm Drug Disposition
1982 Oct-Dec3(4):337-44. doi: 10.1002/bdd.2510030407
Liu J., Chen X., Hu Y., Cheng G., Zhong D.
Quantification of the major metabolites of bromhexine in human plasma using RRLC-MS/MS and its application to pharmacokinetics.
Journal Pharmacy Biomed Anal
2010 Apr 651(5):1134-41. doi: 10.1016/j.jpba.2009.11.024. Epub 2009 Dec 1
Habtemariam S., Nabavi S.F., Ghavami S., Cismaru C.A., Berindan-Neagoe I., Nabavi S.M.
Possible use of the mucolytic drug, bromhexine hydrochloride, as a prophylactic agent against SARS-CoV-2 infection based on its action on the Transmembrane Serine Protease 2.
Pharmacology Research
2020 Jul157:104853. doi: 10.1016/j.phrs.2020.104853. Epub 2020 Apr 30
Alkotaji M.
Azithromycin and ambroxol as potential pharmacotherapy for SARS-CoV-2.
International Journal Antimicrob Agents
2020 Dec56(6):106192. doi: 10.1016/j.ijantimicag.2020.106192. Epub 2020 Oct 10
Gupta P.R.
Ambroxol - Resurgence of an old molecule as an anti-inflammatory agent in chronic obstructive airway diseases.
Lung India
2010 Apr27(2):46-8. doi: 10.4103/0970-2113.63603
Jauch R., Bozler G., Hammer R., Koss F.W., Karlsson M., Vitek E., Haring I., Beschke K., Hadamovsky S., Maass D., Wollmann R.
Separation and quantitative determination of imipramine and desipramine from rat biological samples by high pressure liquid chromatography.
Experientia
197834(11):1486-1488. doi: 10.1007/bf01932369
Maggio R., Corsini G.U.
Repurposing the mucolytic cough suppressant and TMPRSS2 protease inhibitor bromhexine for the prevention and management of SARS-CoV-2 infection.
Pharmacology Research
2020 Jul157:104837. doi: 10.1016/j.phrs.2020.104837. Epub 2020 Apr 22
Olaleye O.A., Kaur M., Onyenaka C.C.
Ambroxol Hydrochloride Inhibits the Interaction between Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein's Receptor Binding Domain and Recombinant Human ACE2. bioRxiv. 2020 Sep 14. doi: 10.1101/2020.09.
13
295691
ATC classification(1 code)
ATC R05CB02
Affected organisms(2)
Rat
Mouse
International brands(5)
Salt forms(1)
Bromhexine hydrochloride(DBSALT001092)
Experimental properties(5)
External resources(1)
Commercial products(1)
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Bromhexine
Additional database identifiers
ChemSpider
2348
BindingDB
50239965
ZINC
ZINC000000608220
HUGO Gene Nomenclature Committee (HGNC)
HGNC:11876
GeneCards
TMPRSS2
Guide to Pharmacology
2421
UniProt Accession
TMPS2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:13557
GenAtlas
ACE2
GeneCards
ACE2
GenBank Gene Database
AF291820
GenBank Protein Database
9802433
Guide to Pharmacology
1614
UniProt Accession
ACE2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:13557
GenAtlas
ACE2
GeneCards
ACE2
GenBank Gene Database
AF291820
GenBank Protein Database
9802433
Guide to Pharmacology
1614
UniProt Accession
ACE2_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Knox C., Wilson M., Klinger C.M., et al
DrugBank 6.
0: the DrugBank Knowledgebase for 2024
Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
Wishart D.S., Feunang Y.D., Guo A.C., et al
DrugBank 5.
0: a major update to the DrugBank database for 2018
Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
Show earlier publications
Law V., Knox C., Djoumbou Y., et al
DrugBank 4.
0: shedding new light on drug metabolism
Nucleic Acids Res. 2014 Jan 142(1):D1091-7
Knox C., Law V., Jewison T., et al
DrugBank 3.
0: a comprehensive resource for 'omics' research on drugs
Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41
Wishart D.S., Knox C., Guo A.C., et al
DrugBank: a knowledgebase for drugs, drug actions and drug targets.
Nucleic Acids Research
2008 Jan36(Database issue):D901-6
Wishart D.S., Knox C., Guo A.C., et al
DrugBank: a comprehensive resource for in silico drug discovery and exploration.
Nucleic Acids Research
2006 Jan 134(Database issue):D668-72
Source: go.drugbank.comCC BY-NC 4.0
Updated 26 days ago(8 Mar 2026)